Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-15 receptor fusion proteins are engineered biologic molecules that combine interleukin-15 (IL-15) or its receptor subunits with other functional domains to enhance its therapeutic potential in cancer immunotherapy. These fusion proteins aim to improve IL-15's stability, half-life, tumor-targeting ability, and immunostimulatory effects while reducing systemic toxicity. Common features include IL-15/IL-15Rα complex, Fc fragment, and targeting motifs (e.g., RGD).
Stimulates proliferation and activation of cytotoxic CD8+ T cells and natural killer (NK) cells, leading to increased anti-tumor immunity. Targets tumors via integrins or antibody-antigen interactions.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-15 Receptor Fusion Protein (IL-15R Fusion Protein).